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Introduction: T cells orchestrate joint inflammation in rheumatoid arthritis (RA), yet they are difficult to study due
to the small numbers of antigen-specific cells. The goal of this study was to characterize a new humanized model
of autoimmune arthritis and to describe the phenotypic and functional changes that occur in autoimmune T cells
following the induction of pathological events.
Methods: We developed a double transgenic mouse containing both the HLA-DR1 transgene and an HLA-DR1-restricted
collagen-specific TCR in order to obtain large numbers of antigen-specific T cells that can be used for immunologic
studies.
Results: In vitro, CII-specific T cells from this mouse proliferated vigorously in response to the CII immunodominant
peptide A2 and the cells altered their phenotype to become predominately CD62Llow and CD44high “activated” T cells.
The response was accompanied by the production of Th1, Th2, and Th17-type cytokines. Following immunization with
bovine CII/CFA, these mice develop an accelerated arthritis compared to single transgenic HLA-DR1 mice. On the other
hand, when the mice were treated orally with the analog peptide A12, (a suppressive analog of collagen we have
previously described), arthritis was significantly suppressed, despite the fact that >90% of the CD4+ T cells express the
TCR Tg. In GALT tissues taken from the A12-treated mice, IL-2, IFN-γ, and IL-17 production to the autoimmune collagen
determinant dropped while high levels of IL-10 and IL-4 were produced.
Conclusions: We have developed a humanized model of autoimmune arthritis that will be useful for the study of
T cell directed therapies as well as T cell mediated mechanisms of autoimmune diseases.Introduction
Although the majority of autoreactive T cells are deleted
in the thymus, it is clear that some escape thymic selec-
tion, and once in the periphery are capable of mediating
an autoimmune response. However, the precise mecha-
nism by which T cell function is altered so that auto-
immune diseases can develop is poorly understood. Some
of the difficulty in deciphering these mechanisms is that
the frequency of the Ag-specific T cells to be targeted is
very limited, estimated to be 104 or less [1]. Here, we* Correspondence: lmyers@uthsc.edu
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reproduction in any medium, provided the ordescribe the development of a double-transgenic mouse
that expresses an autoreactive T cell receptor (TCR)
specific for type II collagen (CII) and the human leukocyte
antigen (HLA) -DRB1*0101, a haplotype susceptible to
the induction of collagen-induced arthritis. These mice
express a TCR specific for the HLA-DR1-restricted im-
munodominant determinant of CII, A2, on >90% of the
CD4+ T cells. Despite the fact that they are capable of
recognizing murine CII (mCII), they are not deleted in the
thymus.
We have analyzed the function of these T cells using the
collagen-induced arthritis model with the goal of deter-
mining the role that autoreactive T cells play in mediating
autoimmune arthritis and in modulating the severity of
the disease. We also investigated whether these autoreac-
tive transgenic T cells could be manipulated to secreted. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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autoimmunity. We have treated these mice orally with an
altered peptide ligand (APL) of collagen to determine how
this therapy influences the cytokine responses of T cells
located in murine gut-associated lymphatic tissue (GALT).
We believe this transgenic (Tg) model can serve as an
excellent vehicle for defining the molecular mechanisms
by which T cells influence autoimmune arthritis and will
help shape the development of future T-cell directed the-
rapies for autoimmune diseases [2].Methods
Preparation of tissue-derived CII and synthetic peptides
The following nomenclature is used to define the antigens
used in this study: type II collagen, CII; bovine type II
collagen, bCII; murine type II collagen, mCII; a peptide
containing the immunodominant determinant sequence
of both bovine and human CII (GIAGFKGEQGPKGEB),
A2; a peptide containing the immunodominant determi-
nant sequence of murine CII (GIAGFKGDQGPKGEB),
mA2; a synthetic peptide representing the sequence
(GIAGNKGDQGPKGEB), A12; the constituent protein
chains of bovine CII isolated by carboxymethyl-cellulose
chromatography, α1(II). B stands for 4-hydroxyproline.
Native type II collagen (CII) was solubilized from fetal
calf articular cartilage or murine articular cartilage by limi-
ted pepsin-digestion and purified as described earlier [3].
The purified collagen was dissolved in cold 10 mM acetic
acid at 4 mg/ml and stored frozen at −70°C until used. In
some experiments denatured α1(II) chains were used. The
synthetic peptides were supplied by Biomolecules Midwest
Inc. (Waterloo, IL, USA).
Animals
Generation of Tg mice expressing DR
Mice expressing the chimeric (human/mouse) DRB1*0101
construct were maintained in our onsite facility. The
chimeric DRB1*0101 construct and the production of Tg
mice expressing this construct have been previously des-
cribed [4].
Generation of double-transgenic (DR1-TCR) mice
The CII-specific TCR-genes in the DR-transgenic mice,
were expressed using the cassette vectors pTαcass and
pTβcass provided by Benoist and Mathis [5]. Rearranged
Vα2/Jα27 and Vβ8.1/D/Jβ2.4 fragments were obtained
from a DR1-restricted A2-specific T cell hybridoma
(E168) by rt-PCR. The PCR fragments were subcloned
into the TCR cassette vectors, using the following modi-
fications. For the α chain construct, a Xma I site was
created 17 bp upstream of the ATG cordon of the TCR-
Vα2/Jα27 cDNA; and an 11-bp sequence that represents
the beginning of the J-C intron was added downstreamof the Jα27 segment, followed by an artificial Not I site.
The resulting cDNA fragment was introduced into the
pTαcass between the Xma I and Not I sites to create the
pTα cass-Vα2. For the β chain construct, a Xho I site
was created 12 bp upstream of the ATG cordon of
Vβ8.1, and a 17 bp untranslated sequence representing
the beginning of the J-C intron was introduced down-
stream of Jβ2.4, followed by a Sac II site. The resulting
cDNA was introduced into the cassette vector pTβcass
between the Xho I and Sac II sites to create pTβcass-
Vβ8.1. The linearized DNA fragments (pTαcass-Vα2 and
pTβcass-Vβ8.1) were simultaneously injected into fer-
tilized eggs of FVB/N mice. Transgenic founders were
identified by PCR analysis of tail DNA. Mice were back-
crossed onto DR1-transgenic C57BL/10 mice to estab-
lish a TCR transgenic mouse line, and then backcrossed
to the HLA-DR1 mice to develop double-transgenic
mice. Mice used in these experiments were from
generations N13 to N14 and were heterozygous for the
TCR transgenes and homozygous for the HLA-DR1
transgene.
All mice were fed standard rodent chow (Ralston Purina
Co., St Louis, MO, USA) and water ad libitum. Sentinel
mice were routinely tested for murine pathogens. Ex-
periments were conducted in accordance with approved
Institutional Animal Care and Use Committee (IACUC)
protocols. Mice were 8 to 12 weeks old.Antibodies
The antibodies (Abs) used for flow cytometry included:
peridinin chlorophyll protein (PerCP)-conjugated anti-CD4
(clone RM4-5), phycoerythrin (PE)-conjugated anti-CD8
(clone 53–6.7), PE-conjugated anti-CD62L (clone Mel-14),
fluorescein isothiocyanate (FITC)-conjugated anti-V β8.1,2
(clone F23.1), APC-conjugated anti-CD44 (clone IM7), and
FITC-conjugated anti-Vα2 (clone: B20.1). All Abs were pur-
chased from BD PharMingen (San Diego, CA, USA) and
used according to the manufacturer’s recommendations.Flow cytometry
Splenocytes, peripheral blood cells, or inguinal lymph
node cells from mice were isolated and the phenotype was
determined by multiparameter flow cytometry using an
LSRII flow cytometer (BD Biosciences, San Jose, CA,
USA). Cells were labeled with fluorochrome antibodies
specific for CD4, CD25, or CD44, (BD Biosciences). In
some experiments intracellular labeling was performed
using antibodies specific for FoxP3 (FJK-16 s, eBioscience,
San Diego, CA, USA). In the experiments involving intra-
cellular staining, gating was performed on both CD4+ and
Vβ8+ cells. A minimum of 10,000 cells was analyzed from
each sample and the final analysis was performed using
FlowJo software (Tree Star, Ashland, OR, USA).
Tang et al. Arthritis Research & Therapy 2014, 16:R7 Page 3 of 13
http://arthritis-research.com/content/16/1/R7Proliferation assays
Spleen cells were cultured with various concentrations
of collagen and collagen peptides in 96-well plates at
4.5 × 105/well in 300 μl of HL-1 medium supplemented
with 50 μM of 2-ME and 0.1% BSA (fraction V, Gig free,
low end toxin; Sigma-Aldrich, St Louis, MO, USA) at 37°C,
5% humidified CO2 for 4 days. Eighteen hours before the
termination of the cultures, 1 μCi of (3H)thymidine (New
England Nuclear, Boston, MA, USA) was added to each
well. Cells were harvested onto glass-fiber filters and
counted on a Matrix 96 direct ionization beta counter
(Packard Instrument, Meriden, CT, USA). Results were
confirmed by replicate experiments and all data are
expressed as disintegrations per minute (dpm).
Immunizations and arthritis induction
Mice were immunized with bCII for the induction of
arthritis. bCII was dissolved in 10 mM cold acetic acid.
The bCII was then emulsified with CFA (Complete
Freund’s Adjuvant) as previously described [3]. Mice were
immunized subcutaneously at the base of the tail with
100 μg of bCII. For other immunizations, either peptide
A12 or Ova emulsified with CFA was given subcutane-
ously so that each mouse received 100 μg of protein.
Measurement of the severity of arthritis
The severity of arthritis was determined by visually
examining each forepaw and hindpaw and scoring them
on a scale of 0 to 4 as described previously [3]. Scoring
was conducted by two examiners, one of whom was un-
aware of the identity of the treatment groups. Each
mouse was scored thrice weekly beginning 3 weeks post
immunization and continuing for 8 weeks. The mean
severity score (sum of the severity scores for the group
on each day/total number of animals in the group) was
recorded at each time point.
Measurement of serum antibody titers
Mice were bled at 4 weeks after immunization and sera
were analyzed for antibodies reactive with native murine
CII using a previously described modification of an ELISA
[3]. Serial dilutions of a standard serum were added to
each plate. From these values, a standard curve was de-
rived by computer analysis using a four-parameter logistic
curve. Results are reported as units of activity, derived by
comparison of test sera with the curve derived from the
standard serum which was arbitrarily defined as having 50
units of activity. Reactivity to mCII was not detected in
sera obtained from normal mice.
Adoptive transfer experiments
Inguinal lymph-node cells from DR1-TCR double-trans-
genic mice previously immunized with either A12 or Ova
in CFA were collected 8 days after immunization and theCD4+ cell subset was fractionated using ferromagnetic
beads (Miltenyi Biotec, Gladbach, Germany) according
to the manufacturer's protocol. The purity of the resul-
ting cell population was confirmed by flow cytometry to
have >95% purity. Recipient mice were given cells intra-
venously and received 5 × 105 cells. All recipient mice
were immunized with bCII on the day of the cell trans-
fer and observed for arthritis.
Oral treatment with peptide
For the study of events following oral administration of the
peptide A12 in the DR1-TCR Tg mice, either A12 or Ova
was dissolved in PBS. DR1-TCR mice were fed doses of 10,
50, or 100 μg A12, or 50 μg Ova by oral gavages three times
a week. The treatments began either the day after im-
munization of mice with bCII/CFA (prevention protocol)
or the day of the onset of arthritis (treatment protocol) and
continued for the duration of the experiment.
Measurement of cytokines
To measure cytokines, in some experiments, naïve spleno-
cytes from DR1-TCR transgenic mice were cultured with
bovine α1(II), A2, mA2, or A12. In other experiments,
DR1-TCR transgenic and DR1 Tg mice were immunized
with bCII/CFA and lymph-node cells were taken from the
mice 10 days after immunization and were cultured with a
peptide representing the immunodominant determinant
of murine collagen (mA2) so that supernatants could be
analyzed for the presence of cytokines. In a third set of ex-
periments, DR1-TCR double-transgenic mice were treated
with 8 doses of 50 μg of either A12 or PBS by oral gavage,
sacrificed after the last gavage and GALT cell populations
were removed. Single-cell suspensions of mesenteric
lymph-node cells and Peyer’s patch cells were made and
pooled prior to culture in 48-well plates in triplicates. Each
well contained 500 μl single cell suspension (5 × 105/ml) +
indicated concentrations of each peptide, or PBS. Media
used were X-VIVO 10 (Biowhittaker, Radnor, PA) for two-
day cultures or DMEM-complete (DMEM+ 1% Pen-strep,
1% 2-ME, 1% glutamax, 1% sodium pyruvate, 10% FBS)
for 6-day cultures. Cells were incubated at 37°C and har-
vested after 72 hours.
Each culture was set up using cells from three mice
run in triplicates and supernatants were analyzed for
the presence of IL-10, IL-4, IFN-γ, and IL-17A using a
Bio-plex mouse cytokine assay (Bio-Rad, Hercules, CA,
USA) according to the manufacturer’s protocol. Values
are expressed as picograms per ml and represent the
mean values for each group taken from three separate
experiments.
Statistical analysis
Mean severity scores, antibody titers, and cytokine levels
were compared using the Mann–Whitney test. The
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exact test.
Results
Generation of the double-transgenic mice
To study the role that T cells play in a milieu that contains
a human transgene (HLA DRB1*0101) that correlates with
susceptibility to human rheumatoid arthritis (RA), a
double-transgenic (DR1-TCR) Tg mouse was developed.
The cDNA encoding an A2-specific TCR was cloned by
RT-PCR from a DR1-restricted T cell hybridoma that re-
cognizes both bCII (immunogen) and mCII (autoantigen).A
C
Figure 1 Development of a double-transgenic DR1-T cell receptor (TC
DR1-TCR Tg mouse model was developed and backcrossed onto DR1 transgen
spleen cells were stained with a combination of anti-Vβ8- fluorescein isothiocy
obtained from the single-transgenic DR1 mouse; (B) representative data obtain
blood cells were obtained from the single-transgenic DR1 mouse (C) and com
antibodies specific for CD4+, Vβ8.1 and Vα2. The majority of the CD4+ cells in
on the analysis of 10,000 gated events with the gate set on forward versus sideThis TCR uses Vα2-Jα27 gene segments and Vβ8.1 Jβ2.4
gene segments similar to other CII-specific DR1-restricted
TCR previously described [6,7]. The Vα and Vβ cDNA
were cloned into the plasmid pTαcass and pTβcass deve-
loped by Mathis and Benoit [5]. Following co-injection,
founders were identified by PCR and immunofluorescence
and backcrossed to mice bearing the DR1 transgene [4].
As shown in Figure 1, the Vβ8 transgene was expressed
by >90% of the α/βTCR T cell population of the spleen
(Figure 1B), which is significantly higher than the 9% of
the α/βTCR + cells that express the endogenous Vβ8
in the non-Tg littermates (Figure 1A). Similarly, whenB
D
R) Tg mouse model of autoimmune arthritis. The double-transgenic
ic mice as described in Methods. To detect the presence of the transgene,
anate (FITC) and anti- TCR-phycoerythrin (PE). (A) Representative data
ed from the double-transgenic mouse. In a similar manner, peripheral
pared to cells from the double-transgenic mouse (D), staining with
the double-transgenic mouse express both Vβ8.1 and Vα2. Data are based
scatter to exclude non-lymphoid cells and dead cells.
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are co-expressed on the majority of the CD4+ T cells from
the double-transgenic mice (panel D) compared to cells
from the DR1 single-transgenic mice (Figure 1C).
Phenotype of TCR T cells
The TCR Tg is fully functional as measured by the ability
of the T cells to proliferate specifically in response to
peptide presentation by DR1. When Tg T cells were
stimulated in vitro with either bovine α1(II) or A2, the
cells proliferated vigorously and induced a full array of
cytokines (IFN-γ, IL-17, IL-10) in the presence of anti-
gen presenting cells (APCs) (Figure 2). No proliferative























































Figure 2 Naive spleen cells from DR1-T cell receptor (TCR) Tg mice re
DR1-TCR Tg mice were cultured with human A2, murine A2, A12 or bovine α1(
was measured by incorporation of (3H)-thymidine and is expressed as the mean
as means ± standard error of the mean of experiments using three separate mic
induced to either human A2 or bovine α1(II) when comparing proliferation, IFN
differ significantly from the responses to human A2, α 1(II) and murine A2 in pro
A12-induced IL-10 response was not different.littermates did not proliferate (data not shown). More-
over, we demonstrated that these T cells are cross-
reactive with mA2, demonstrating both proliferation and
a full array of cytokines, although these responses were
weaker than those induced by A2 (Figure 2). These data
reflect our prior observation that changing the Asp (A2)
at residue 266 to Glu (mA2), which is the residue that
interacts with the P4 binding pocket of the HLA-DR1,
causes a lower affinity of binding to the DR1, inducing a
weaker response from the transgenic T cells compared
to that induced by A2 [8]. On the other hand, the A12
peptide, which contains amino acid substitutions at posi-
tions 263 (N) and 266 (D) so that interaction with both











































spond to culture with type II collagen (CII). Spleen cells from naive
II) chains with titrated doses. Cytokines are expressed as pg/ml. Proliferation
disintegrations per minute (dpm) of triplicate cultures. Data are expressed
e. Responses to the murine determinant differ significantly from those
-γ, IL-17, or IL-10 (P ≤0.05 using the Mann–Whitney test). Responses to A12
liferation, IFN- γ and IL-17 (P ≤0.05 using the Mann–Whitney test) but the
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from the transgenic T cells (Figure 2) unaccompanied by
proliferative or inflammatory cytokine responses.
In order to compare autoreactive T cell responses from
the double-transgenic T cells with those from the single-
transgenic DR1 mice, we immunized mice with bCII and
cultured the lymph-node T cells with the mA2 peptide
in the presence of APCs (Table 1). The resulting super-
natants demonstrated a vigorous production of T helper
(Th)1, Th2, and Th17 cytokines that were greater than
those induced by T cells obtained from CII-immunized
single-transgenic DR1 mice. The differences were most
striking in the inflammatory profiles (Table 1). Taken
together, these data demonstrate that these double-
transgenic T cells recognize the primary autoantigenic
determinants of murine CII and the exaggerated res-
ponses reflect the presence of a large number of fully
functional CII-reactive T cells.
To evaluate phenotypic changes, CD4+ splenocytes
were cultured with A2 in the presence of APCs and tested
for activation and memory-marker expression (Figure 3A).
These analyses revealed that as early as 24 h post culture,
the expression levels of two cell-surface markers asso-
ciated with the activation/memory phenotypes, CD44high
and CD62Llow, underwent marked shifts. The vast majo-
rity of the A2-cultured cells now expressed CD44high and
CD62low compared to cells cultured with a control analog
peptide A12 or cells cultured with media alone. Only, 9.7
percent of the T cells cultured with A2 expressed the
Treg-associated nuclear transcription factor Foxp3, similar
to the percentages of Tregs identified in cultures of cells
incubated with media alone. Thus, using this model, we
have demonstrated that challenge with peptide A2 induces
the majority of the T cells to enter a period of activation,
acquiring a memory phenotype.
Similarly, when α1(II) was administered in vivo to the
double transgenic mice, the CD4+ T cells tested directly
ex vivo were found to have increased numbers of activated
CD44hi and CD62Llo CD4+ cells (Figure 3B). On the otherTable 1 Cytokines produced in response to murine collagen
Mouse Culture
IFN
DR1/TCRtg No Ag (antigen) 0
mA2 (3 μmol/ml) 13,522
mA2 (0.3 μmol/ml) 5,167
DR1 No Ag (antigen) 59 ±
mA2 (3 μmol/ml) 1,116 ±
mA2 (0.3 μmol/ml) 737 ±
Inguinal lymph-node cells from type II collagen (CII)-immunized DR1 or DR1-T cell rece
were cultured with peptide mA2 so that supernatants could be analyzed for the prese
the mean of three separate experiments. When cultures from DR1/TCR tg mice were c
elevated, T helper (Th)1, Th2, and Th17. *P ≤0.01 when mA2 responses from DR1 mice
murine A2 peptide.hand, the addition of the A12 peptide significantly de-
creased the expression of activation markers. Staining for
intracellular Foxp3 did not reveal differences between the
two groups tested directly ex vivo (Figure 3B).
Induction of autoantibodies and disease in DR1-TCR Tg
mice
When the Tg mice were immunized with bCII/CFA, they
developed a strong T cell-dependent Ab response to the
autoantigen, mCII (Figure 4), greater than that elicited in
control mice bearing only the DR1 transgene The in-
creases were pronounced in both immunoglobulin (Ig)G2
and IgG1 subsets. Moreover, offspring from the double-
transgenic founders developed a more severe form of
disease as compared with the DR1 littermates, as mea-
sured by both severity scores and the number of arthritic
limbs (Figure 5, panels A and B). Although both groups of
mice developed arthritis around 20 days after immunization
and continued to progress in severity until the end of the
experiment (day 55), the severity scores were markedly dif-
ferent (P = 0.009). Histology confirmed that the double-
transgenic mice had greater pannus formation and cartilage
destruction when compared to arthritic DR1 mice (Figure 5,
panel C). We have not observed spontaneous arthritis in
the double-transgenic mice up to 24 months of age, despite
large numbers of CII-specific T cells.
Induction of suppression of arthritis
Based on the overwhelming T cell response and accele-
rated arthritis development, we wondered whether it
would be possible to suppress the severity of the auto-
immune arthritis. To resolve whether inflammatory T cells
from the double-transgenic mice could successfully be
shut down or redirected, we treated them with an altered
peptide ligand of CII, A12, which we have previously
described, and performed adoptive-transfer experiments
[9]. Draining inguinal lymph-node cells from DR1-TCR
Tg mice previously immunized with A12/ CFA or DR1
mice immunized with OVA/CFA alone were collected andCytokines (pg/ml)
-γ IL-17 IL-4
17 ± 5 0
± 154 9,849 ± 255 297 ± 24
± 95 5,206 ± 175 142 ± 19
11 184 ± 43 23 ± 12
22* 1,082 ± 155* 85 ± 18*
38* 695 ± 29* 42 ± 11*
ptor (TCR) Tg mice were taken from the mice 10 days after immunization and
nce of cytokines. The numbers indicated represent the means ± standard error of
ompared with those from DR1 mice, the cytokine responses to collagen were all
were compared with mA2 responses from DR1-TCR/tg mice. Ag, antigen; mA2,
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Figure 3 (See legend on next page.)
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Figure 3 Phenotype of splenocytes from double-transgenic mice cultured with peptides. (A) CD4+ splenocytes from double-transgenic
mice cultured with peptide A2, developed a CD62Lhi CD62Llo memory phenotype, whereas CD4+ cultured with A12 peptide or media alone did
not change (%CD44hiCD62LloCD4+ T cells = 18 ± 3 for No Ag, 23 ± 5 for A12, and 47 ± 6 for A2; P ≤0.002 for A2 versus No Ag and P ≤0.006 for A2
versus A12). Splenocytes from the double-transgenic mouse cultured with peptide A2 or A12 had no significant differences in numbers of Treg
cells (%CD25hiFoxp3hiCD4+ T cells = 8 ± 2 for No Ag, 9 ± 2 for A12, and 9 ± 3 for A2). (B) Phenotype of splenocytes from double-transgenic mice
tested directly ex vivo: α1(II) was administered in vivo (100 μg/mouse intravenously) alone, or with 100 μg peptide A12. Three days later, CD4+ T
cells treated with α1(II) developed a CD62Lhi CD62Llo memory phenotype, whereas A12 peptide significantly decreased expression of activation
markers (%CD44hiCD62LloCD4+ T cells = 22 ± 7 for A12 + α1(II)-treated mice, and 37 ± 6 for α1(II)-treated mice; P ≤0.02 for α1(II)-treated versus α1
(II) + A12 treated). Staining for intracellular Foxp3 was not different between groups tested directly ex vivo (15 ± 7 for α1(II)-treated mice versus
13 ± 5 for α1(II) + A12-treated mice. Negative control (naïve double-transgenic T cells) had the pattern: (%CD44hiCD62LloCD4+ T cells = 16 ± 4 and
Foxp3 + CD4 T cells = 12 ± 5). Data representative of three separate experiments (A and B).
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ther A12-immune or control CD4+ T cells were infused
intravenously into DR1 tg mice prior to immunization with
bCII/CFA, so that mice could be observed for effects on
collagen-induced arthritis. When infused prior to the in-
duction of arthritis, we observed (Figure 6, panel A), that
the A12-immune T cells from the double-transgenic mice
were extremely effective in suppressing arthritis, compared
to control cells. Mean antibody titers to murine CII taken




































Figure 4 Production of antibody (Ab) specific for murine type II colla
mice. Double- and single-transgenic littermates were immunized with 100
described in Methods. Serum samples were collected 27 days after immun
Ab were calculated using standard reference sera. Data are expressed as m
titers, double-transgenic versus single-transgenic, 180.5 ± 34 versus 50.2 ± 1
61.5 ± 22.3 versus 12.3 ± 6.1, P = 0.007; IgG2b titers 143.45.9 versus 51.3 ± 16the A12-immune T cells, compared to mice given CD4+
control T cells (52.2 ± 16 in mice given control cells versus
11 ± 7 in mice given A12-immune cell, P ≤0.005).
Treatment of arthritis
Our priority, however, was to establish whether arthritis
could be suppressed in the double-transgenic mice once
the immune response had been established. We elected
to use the oral route of administration, a route more
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μg of bCII emulsified in CFA (Complete Freund’s Adjuvant) as
ization and analyzed for quantity of mCII-specific Ab by ELISA. Units of
ean titers of 10 mice per group ± standard error of the mean (total IgG
1, P = 0.001; IgG1 titers, double-transgenic versus single-transgenic:





Figure 5 Disease severity in DR1-T cell receptor (TCR) Tg mice (panels A and B). The severity (panel A) and percentage of arthritic limbs
(panel B) of disease in double-transgenic mice (squares, n = 13) compared with DR1 Tg littermate controls (diamonds, n = 15). All animals were
challenged with a dose of 100 μg of bovine type II collagen (bCII) emulsified in CFA (Complete Freund’s Adjuvant) for the induction of disease.
Mice were scored for arthritis severity as described in Methods. Panel A, P = 0.009 on day 55 when comparing the mean severity scores ± standard
error of the mean using the Mann–Whitney test; panel B, P = 0.002 on day 55 when comparing the number of arthritic limbs using Fischer’s exact
test. The final incidence was 70% for the single-transgenic mice and 90% for the double-transgenic mice. Histology of joints of arthritic animals
(panel C): left, joint from double-transgenic animal showing more eroding pannus and greater amounts of damaged articular cartilage compared
to a representative joint (right), from a single-transgenic animal. The animals were sacrificed eight weeks after immunization. Joints were collected,
fixed with formaldehyde, and decalcified prior to staining with H&E. The tissues were photographed using an inverted-phase contrast microscope
(original magnification: 50×). The data shown are representative of data obtained by analyzing numerous sections from hindpaws taken from 6
animals per group.
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preventive protocol (Figure 6, panel B), we found that
A12 significantly reduced the severity of arthritis in thedouble-Tg mice. The mice treated with OVA developed
arthritis at an expected accelerated rate, whereas by the
A12-treated mice had significantly less severe disease.
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Figure 6 Treatment with either A12-immune cells or A12
peptide can suppress arthritis. Panel A: CD4+ T cells from the
double transgenic mice treated with A12 can transfer the suppression
of arthritis. Single-transgenic DR1 mice (10/group) were infused with
5 × 105 cells of A12-primed CD4+ T cells from double-transgenic mice or
Ova-primed CD4+ T cells from single-transgenic DR1 mice. Recipient
animals were immunized with bovine type II collagen (bCII)/CFA and
observed for arthritis. Only A12-immune cells prevented collagen-induced
arthritis (final severity scores 1.0 ± 0.5 versus 7.4 ± 1.2, P ≤0.0001; final
incidence 90% versus 10% in the treatment group). (Panel B) Oral
treatment with peptide A12 (prevention protocol). Groups of 12
double-transgenic mice were administered PBS or A12 peptide (oral gavage
three times/week), beginning the day after immunization with bCII/
CFA, continuing for the duration of the experiment. On day 46, mice
fed PBS had a severity score of 4.5 ± 0.4, which differed from mice fed
10 μg of A12 (2.4 ± 0.5, P ≤0.05) and mice fed 50 μg of A12 (1.5 ± 0.04,
P ≤0.01; final incidence = 80% in the control and 20% in the 50-μg
group). (Panel C) Oral treatment with peptide A12 (treatment protocol).
Groups of 10 double-transgenic mice were administered PBS or A12
peptide (50 μg/dose, oral gavage three times/week) beginning the
day of arthritis onset. On day 46, mice fed PBS had a severity score of
6.8 ± 0.6, which differed from mice fed 50 μg of A12 (3.6 ± 0.4, P ≤0.05)
(Mann–Whitney test). (Final incidence = 90% in controls and 60% in
the treatment group).
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curve with the 50 μg dose having the greatest effect on
arthritis with protection afforded for the duration of the
treatment. Mice treated with ether 10 μg or 100 μg had
less suppression (Figure 6, panel B). In another set of ex-
periments, mice were treated with the A12 peptide using
a treatment protocol. Mice were fed daily doses of either
PBS or 50 μg if A12, beginning the day of the onset of
arthritis (Figure 6, panel C). Again, oral treatment with
A12 significantly attenuated the severity of arthritis.
Cytokine analysis
The GALT is constituted of a wide variety of cells, which
are often grouped in complex structures, such as Peyer’s
patches, mesenteric lymph nodes or isolated lymphoid fol-
licles, or spread throughout the lamina propria. As orally
ingested substances invariably reach the intestines, are
absorbed by the organism and sampled by the immune
system, pooled cells from Peyer’s patches and mesenteric
lymph-node cells were recovered directly ex vivo, and
tested for cytokine production following oral treatment
with A12. When GALT cells were recovered from mice
given A12 orally in the prevention protocol and cultured
with mA2 the supernatants revealed an enhanced produc-
tion of the suppressive cytokines IL-10 and IL-4 (Table 2).
In contrast, IFN-γ and IL-17 production was significantly
reduced compared to mice that were treated with PBS
(Table 2). Collectively, the in vivo and in vitro experiments
confirm that the suppression of arthritis by A12-specific
T cells involves active secretion of suppressive cytokines
resulting in downregulation of the inflammatory cytokines
IL17 and IFN-γ.
Table 2 Cytokine responses from mice treated with oral
A12
Treatment Culture Cytokines (pg/ml)
IFN-γ IL-17 IL-10 IL-4
PBS No Ag 10 ± 7 17 ± 8 17 ± 10 5 ± 3
mA2 280 ± 22 256 ± 28 45 ± 14 25 ± 6
A12 No Ag 2 ± 3 2 ± 1 15 ± 9 4 ± 3
mA2 12 ± 20* 2 ± 2* 105 ± 18* 48 ± 8*
Pooled cells from Peyer’s patches and mesenteric lymph nodes from A12-treated
DR1/T cell receptor (TCR) Tg mice were taken from the mice 10 days after treatment
with oral gavage was completed, and were cultured with murine A2 peptide (mA2)
(3 μmol/ml) so that supernatants could be analyzed for the presence of cytokines.
When cultures from mice treated with A12 were compared with those from mice
treated with PBS alone, the IL-10 response to mA2 was elevated whereas the
inflammatory cytokines (IFN-γ and IL-17), were suppressed. The numbers indicated
represent the means ± standard error of the mean of three separate experiments.
*P ≤0.01 when type II collagen (CII) responses from A12-treated mice were
compared with CII responses from untreated mice.
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One of the key roles of the immune system is to protect
the organism against infectious diseases and cancer, while
avoiding autoimmune damage. Although T cell responses
are expected to be tightly regulated to prevent T cell hy-
peractivation, which may lead to autoimmune pathology,
our data clearly demonstrate that autoreactive T cells can
be activated and induced to secrete inflammatory cyto-
kines, causing significant tissue damage, and playing a
major role in increasing the severity of autoimmune
arthritis. Although others have previously observed that
T cells play a critical role in autoimmunity in other ani-
mal models, that is, proteoglycan (PG)-induced arthritis
(PGIA) and K/BxN spontaneous arthritis [10] as well as
collagen-induced arthritis (CIA) [11], the ability to make
double-transgenic mice that have a large number of T
cells restricted by the common RA-susceptible major
histocompatibility complex (MHC) molecule, DRB*0101
(DR1), allows greater ease and clarity in investigating the
mechanisms by which T cells become dysregulated during
the initiation of arthritis or how their behavior is altered
when exposed to new therapies.
We demonstrated that in the CIA autoimmune arthritis
model, immunization with bCII/CFA causes an acce-
lerated and more severe arthritis compared to mice bear-
ing only the HLA-DR1 transgene. In vitro, bCII-specific
double-transgenic T cells readily demonstrate both pro-
liferation and production of Th1, Th2, and Th17-type
cytokines when challenged with the A2 peptide, reflecting
the presence of a large number of fully functional CII-
reactive T cells. Using this model, we have confirmed that
activation of a large number of DR1-restricted auto-
immune CD4+ T cells enhances the severity of the arth-
ritis, and this phenomenon is associated with both
increased numbers of autoantibodies and enhanced levels
of inflammatory cytokines. These data reflect the concept
that T-cell recognition of a systemically expressed self-peptide can lead to more severe disease, and that inflam-
matory CD4 + T-cells are dysregulated in autoimmune
arthritis [12-15].
On the other hand, an understanding of the mecha-
nisms by which T cells can be manipulated to control
disease is critical if T cell-specific therapies are to be
successfully implemented. CD4+ helper T cells differen-
tiate into specialized subsets, which attain restricted pat-
terns of cytokine secretion and specific expression of
master transcription factors in response to pathogens
[16]. However, some of the distinctions between these
groups are beginning to blur. Therefore, it becomes im-
perative to clearly define the functional and phenotypic
attributes of autoreactive cells during the induction of
suppression.
We have used the new humanized double-transgenic
model of arthritis to test oral administration of the altered
peptide ligand A12 peptide and to demonstrate that
T cells found in the GALT tissues release IL-10 and IL-4
in response to a murine autoantigen [17]. Our therapy is
based on our previous discovery that A12 could pro-
foundly suppress arthritis in the CIA model by inducing a
unique inhibitory T cell [18]. When the A12 peptide was
administered orally to double-transgenic mice, arthritis
was significantly suppressed, despite the fact that >90% of
the CD4+ T cells express the Tg. The IL-2, IFN-γ, and
IL-17 production dropped and was replaced by IL-10 and
IL-4. The response to A12 was dose dependent, with low
doses being more effective than high doses. We believe
that the bell-shaped curve induced by oral A12, is consis-
tent with antigen processing by the GALT, leading to T
cell cytokine secretion. Other investigators have reported
that proteins administered orally in low doses require the
induction of both IL-4 and IL-10 to suppress disease and
that this induction is consistent with processing by the
GALT. High doses of antigens involve a different mecha-
nism [19,20]. Our finding that A12 stimulates the secre-
tion of IL-4 and IL-10 in GALT tissues, leading to
suppression of arthritis, is consistent with evidence from
other animal models, showing that release of IL-10 and
IL-4 [17] inhibits inflammatory bowel disease [21],
experimental autoimmune encephalomyelitis [22], and
diabetes [17].
The success of the best-known altered peptide ligand
(APL), Copaxone (glatiramer acetate) as a T cell-directed
first-line therapy for multiple sclerosis (MS), suggests
that peptide therapies based on naturally occurring
proteins may provide an effective first-line alternative to
biologic drugs for the treatment of arthritis and that
animal models play a critical role in determining their
efficacy and safety profiles. Although earlier clinical trials
of glatiramer had conflicting results, two more recent
trials have demonstrated its efficacy in treating MS, that
is, the phase-3, randomized CONFIRM trial [23-26] and a
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(CombiRx Trial) [27]. Its safety profile suggests that
drugs based on APLs will have an excellent risk/benefit
ratio [28].
We believe that this double-transgenic animal model of
arthritis will be useful for the development and refinement
of increasingly more sophisticated T cell-directed thera-
pies for RA [29,30]. The difficulty of obtaining human
GALT suggests that murine models will be invaluable in
precisely delineating the role that T cells play when the-
rapies are administered orally.Conclusions
This study provides a detailed description of the pheno-
type of a new double-transgenic (DR1, CII-specific TCR)
mouse. We believe that this mouse will become an impor-
tant tool to allow careful dissection of the role that T cells
play in regulating autoimmune arthritis, and may shape
new therapeutic approaches to autoimmune diseases. As
several strategies for enhancing the efficacy of adoptive T
cell therapy have been developed and introduced in cli-
nical settings [31], we believe that this humanized arthritis
model will be invaluable in advancing our understanding
of the mechanisms that control the pathogenesis of RA.
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